When we win together in 2019, Lisa’s plan for investing in health care will target areas that have been ignored for far too long and will protect our society’s most vulnerable citizens
Lisa's heath care care plan would be built around four pillars:
Canadian Autism Partnership
Early detection is the key. Lisa's plan will provide enhanced training to all medical professionals and childcare workers to recognize the potential signs of Autism and what steps they should take. It will provide direct support to all families of children with autism, recognizing the unique financial burdens they are forced to bear. By making prescribed health care costs related to the treatment and management of Autism Spectrum Disorder (ASD) tax deductible the federal government can make a meaningful impact in the lives of Canadians and ensure children receive the care they need.
National Dementia Strategy
Dementia currently affects close to one million Canadians, robbing them of their quality of life and stretching our social, health and housingresources. Decisive action by the federal government is urgently needed as the proportion of seniors will continue to grow over the coming decades. Now is the time for Canada to implement a National Dementia Strategy based on the recommendations from the Senate’s Dementia/Alzheimer’s report from last fall.
Most patients with rare disorders face a struggle for the proper diagnosis and treatment that could save or significantly improve lives. Opportunities exist to provide information sooner for clinicians and caregivers to manage patients more efficiently.
Efficiency and Innovation
Canada needs to move to a national approach on Drug Coverage, a single plan administered by one body to consolidate buying power and provide common coverage to all Canadians. This common sense coverage approach would also move quickly to allow biosimilars to be used across Canada. This would remove barriers to get biosimilars into the Canadians market and create a system where they are used more widely because biosimilar drugs can realize 10 to 70 per cent in savings to taxpayers while maintaining patient care.
A biosimilar is a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product.
The federal government must do more to both facilitate transformation and to work directly with provinces and territories scaling up and spreading health care delivery models that show promise and deliver superior outcomes. Elements to this strategy include:
The eight agencies are the Canadian Institute for Health Information, Canadian Agency for Drugs and Technologies in Health, Canada Health Infoway, Canadian Foundation for Healthcare Improvement, Canadian Patient Safety Institute, Canadian Centre for Substance Abuse, Canadian Partnership against Cancer and the Mental Health Commission of Canada. In addition, the federal government gives more than $1 billion annually to the Canadian Institute for Health Research.
All Canadians, and our provincial health delivery systems, would benefit from a streamlining of these organizations to reduce duplication and optimize expenditures.
A new consolidated entity should be established with a view to rolling up seven of these agencies into one Research and Transformation Agency, along with the stand alone Mental Health Commission. This new entity will be charged with stimulating and advancing health innovation in Canada by seeding and scaling promising health delivery models that better serve our patients ensuring Canada becomes a leader in health research.